
Contents

Part I: Basics	5	Image Fusion	49
		U. PIETRZYK	
1 Physical Principles, Dedicated/ Coincidence-PET	3	5.1 Introduction	49
S. ZIEGLER		5.2 Basic Remarks	49
1.1 Physics Background	3	5.3 Properties of PET, SPECT, CT and MR Images Relevant for Image Fusion	50
1.2 Detectors for PET	4	5.4 Technical Issues in Image Fusion	50
1.3 Tomograph Design	5	5.5 Image Fusion in Brain Imaging	53
2 Dual-Modality PET/CT Acquisition Systems for Clinical Oncology	9	5.6 Image Fusion Strategies for Extra-cranial Images	54
T. BEYER AND D. W. TOWNSEND		5.7 Combined Devices for Functional- Anatomical Imaging (PET/CT)	55
2.1 Adding Anatomical to Functional Information	9	6 PET Scanner Quality Control	59
2.2 Anato-metabolic Imaging: The Proof-of- principle for Dual-Modality Imaging	11	T.-G. TURKINGTON	
2.3 PET/CT Design Considerations: The Second Generation of PET/CT Tomographs	15	6.1 Quality Control Issues	59
2.4 Experiences with Existing PET/CT Technology	19	6.2 Basic Ring Function and the Sinogram	59
2.5 Recent Developments and Trends for Tomorrow	25	6.3 Impact of Malfunctioning Detectors	62
3 Transport and Metabolism of Glucose and FDG	30	6.4 A Simple Daily Protocol	63
P. OEHR		6.5 Quantitative Accuracy	63
3.1 Biological Functions of Carbohydrate Metabolism	30	6.6 Determining Whether or Not to Scan	64
3.2 Metabolism of Glucose, 2-DG, 2-FDG and 3-FDG	31	Part II: Experimental Oncology	
3.3 FDG Uptake	33	7 Introduction to Experimental PET in Oncology	67
4 Radiopharmaceutical Production and Safety of [¹⁸F]FDG	43	P. OEHR	
P. OEHR		7.1 PET and Molecular Imaging	67
4.1 Radiopharmaceutical Chemistry of [¹⁸F]FDG	43	7.2 Assay Models for Experimental PET	67
4.2 [¹⁸F]FDG Pharmacokinetics, Toxicity and Interactions	45	7.3 Conclusions	71
4.3 [¹⁸F]FDG Activity Dosages and Radiation Exposure	46	8 PET in Cell Cultures: Oncology, Genetics, and Therapy	73
4.4 Conclusions	47	P. OEHR, N. GILBERT, H. LEMMOCH, M. LUDWIG, R. WAGNER, H. SCHÜLLER, AND H. RINK	
		8.1 Introduction	73
		8.2 Material and Methods	73
		8.3 Results	74
		8.4 Discussion	74
		8.5 Conclusion	75

9	Small-Animal PET in Oncology	77	13	Head and Neck Tumors	127
	M. HONER, M. BRÜHLMEIER, I. NOVAK-HOFER, AND S. AMETAMEY			H. BENDER AND H.-J. STRAEHLER-POHL	
9.1	Dedicated Small-Animal PET Cameras	77	13.1	Incidence, Etiology and Epidemiology	127
9.2	Applications of Small-Animal PET in Oncology	79	13.2	Histopathology	127
10	Small-Animal PET in Neuro-oncology and Gene Therapy	87	13.3	Conventional Diagnostic Procedures	128
	A.H. JACOBS AND W.-D. HEISS		13.4	Functional Imaging/FDG PET	129
10.1	Introduction	87	13.5	Summary and Outlook	133
10.2	Gliomas – General and Molecular Aspects	87	13.6	Technical Recommendations	134
10.3	Gene Therapy for Gliomas – Current Status and Future Perspectives	88	14	Thyroid Carcinomas	137
10.4	Small-Animal PET – Imaging of Endogenous Gene Expression for Characterization of Target Tissue	88		F. GRÜNWARD AND M. DIEHL	
10.5	Small-Animal PET – Imaging of Expression of Exogenously Introduced Genes	90	14.1	Clinical Background	137
10.6	Summary and Conclusion	94	14.2	Therapy	137
			14.3	Use of FDG PET	139
			14.4	Indications	144
			14.5	Results and Interpretation	145
			14.6	Limits of Interpretation	146
			15	Lung Cancer	149
				J.-F. VANSTEENKISTE AND S.S. STROOBANTS	
			15.1	Incidence, Etiology and Epidemiology	149
			15.2	Histopathological Classification	149
			15.3	Conventional Diagnostic Procedures	150
			15.4	PET	153
			15.5	Indications for PET – Practical Clinical Guidelines	158
			15.6	New Tracer Developments	160
			15.7	Summary and Outlook	161
			15.8	Technical Recommendations	161
			16	Breast Cancer	167
				H. PALMEDO	
			16.1	Incidence and Epidemiology	167
			16.2	Histopathological Classification, Pathology and Prognosis of Breast Cancer	167
			16.3	Conventional Diagnostic Procedures and Treatment Strategies	168
			16.4	PET in Breast Cancer	171
			16.5	Indications	175
			16.6	Technical Recommendations	176
			17	Pancreatic Cancer	179
				D. DELBEKE	
			17.1	Epidemiology and Histopathological Types	179
			17.2	Conventional Diagnostic Imaging Modalities	179
			17.3	FDG PET Imaging	180
			17.4	FDG PET for Evaluation of Islet Cells and Other Endocrine Tumors of the Pancreas	183
			17.5	Summary	184
Part III: Clinical Applications					
11	PET/CT: Clinical Considerations	101			
	A. BOCKISCH, L. FREUDENBERG, G. ANTOCH, AND ST. MÜLLER				
11.1	Introduction	101			
11.2	Present State and Use of PET/CT	102			
11.3	Clinical Value of PET/CT at Present	102			
11.4	Patient Selection and Clinical Protocols for PET/CT Scanning	105			
11.5	Clinical Impact of PET/CT	105			
12	Brain Tumors	113			
	T.-Z. WONG, G.-J. VAN DER WESTHUIZEN, AND R.-E. COLEMAN				
12.1	Incidence, Etiology, Epidemiology	113			
12.2	Histopathological Classification	113			
12.3	Imaging of Brain Tumors	114			
12.4	FDG PET Imaging of Brain Tumors	114			
12.5	Indications for FDG PET Imaging of Brain Tumors	115			
12.6	Other PET Tracers	119			
12.7	Summary and Outlook	121			
12.8	Technical Recommendations	121			

18 Gastro-Esophageal Cancer	187	22.4 Diagnosis, Staging and Prognostic Factors ..	237
P. FLAMEN AND L. MORTELMANS		22.5 Evidence for the Use of 18F-FDG PET	
18.1 Introduction	187	in the Management of Cervical Cancer	238
18.2 PET: Current Status	189	22.6 Technical Recommendations	240
18.3 Indications of PET	199	22.7 Conclusion	240
18.4 New Tracer Developments	199		
18.5 Summary	200	23 PET in Bladder, Renal,	
18.6 Technical Recommendations	200	and Prostate Cancer	243
		M. SELTZER AND O. SHVARTS	
19 Liver Cancer	203	23.1 Introduction	243
J.-H. RISSE		23.2 Bladder Cancer	243
19.1 Incidence, Etiology and Epidemiology	203	23.3 Renal Cancer	244
19.2 Histopathological Classification	203	23.4 Prostate Cancer	245
19.3 Conventional Diagnostic Procedures		23.5 Summary	247
and Treatment Strategies	204		
19.4 PET: Current Status in Liver Cancer	205	24 Testicular Tumors	251
19.5 Judgement of Indications of PET		P. ALBERS	
in Liver Cancer	209	24.1 Incidence, Epidemiology and Clinical	
19.6 New Tracer Developments	209	Diagnosis	251
19.7 Summary and Outlook	209	24.2 Pathological Diagnosis and Classification ..	251
19.8 Technical Recommendations	209	24.3 PET in Diagnosis and Treatment	253
		24.4 Summary and Future Directions	256
20 Colorectal Cancer	213		
M. T. KITAPCI AND R. E. COLEMAN		25 Malignant Melanoma	259
20.1 Introduction	213	P. PAQUET, R. HUSTINX, P. RIGO,	
20.2 Diagnosis	215	AND G.E. PIÉRARD	
20.3 FDG PET Imaging for Colorectal		25.1 Introduction	259
Cancer: Current State	216	25.2 Rationale for Using 18-FDG	
20.4 Impact on Patient Management	223	as a Radiotracer in Melanoma	260
20.5 Assessment of Prognosis		25.3 Sensitivity and Specificity of 18-FDG-PET	
and Cost-Effectiveness	223	in Cutaneous Melanoma	261
20.6 Limitations	223	25.4 FDG-PET Versus Conventional Imaging	
20.7 Summary	224	in Melanoma	262
20.8 New Tracers	224	25.5 Pitfalls of FDG-PET in Melanoma	263
20.9 Technical Recommendations	224	25.6 FDG-PET in Ocular Melanoma	264
		25.7. New Radiotracers for Melanoma	264
21 Ovarian Cancer	227	25.8 Conclusion	264
M. ZIMNY			
21.1 Incidence, Etiology, Epidemiology	227	26 Malignant Lymphomas	267
21.2 Histological Classification	227	C. MENZEL	
21.3 Diagnosis and Treatment		26.1 Hodgkin's disease	267
of Ovarian Cancer	227	26.2 Non-Hodgkin's Lymphoma	270
21.4 Positron Emission Tomography	228		
21.5 Summary	232	27 Musculoskeletal Tumors	275
21.6 Technical Recommendations	232	A.K. BUCK, H. SCHIRRMEISTER,	
		AND S.N. RESKE	
22 Cancer of the Uterus	237	27.1 Incidence, Etiology, Epidemiology	275
M.-J. REINHARDT		27.2 Histopathological Classification	276
22.1 Preface	237	27.3 Conventional Diagnostic Procedures	
22.2 Epidemiology	237	and Treatment Strategies	277
22.3 Pattern of Spread and Histology	237	27.4 Positron Emission Tomography	278

27.5	Judgement of Indications for FDG-PET	280	31	Cancer Screening with 18F FDG-PET	309
27.6	New Tracer Developments	281		K. NAKAI, S. YASUDA, M. IDE,	
27.7	Summary and Outlook	281		S. KAWADA, AND A. SHOHTSU	
27.8	Technical Recommendations	283			
28	Skeletal imaging with F-18	285			
	H. PALMEDO				
28.1	Background	285	31.1.	Background	309
28.2	Conventional Screening for Bone Metastases	287	31.2.	Subjects and Methods	309
28.3	PET with F-18 Sodium Fluoride for Metastatic Bone Disease	287	31.3.	Results	309
28.4	Technical Recommendations	289	31.4.	Cancer Screening	310
29	PET in Surgery	291	31.5.	Conclusions	320
	S. YASUDA, K. NAKAI, M. IDE, S. KAWADA, AND A. SHOHTSU		32	Cost-Effectiveness Studies of PET in Oncology	321
29.1	Introduction	291		K. A. MILES AND L. B. CONNELLY	
29.2	Advantages of FDG-PET	291	32.1	Introduction	321
29.3	Limitations of FDG-PET	291	32.2	Definitions	321
29.4	Applications of FDG PET in Surgery	292	32.3	Techniques for Assessing Cost- Effectiveness	324
29.5	Summary	299	32.4	Cost-Effectiveness Studies of PET in Oncology	326
30	PET and Radiotherapy	303	32.5	Translating the Results of Cost- Effectiveness Studies to Other Countries . . .	328
	VAL J. LOWE		32.6	Summary	329
30.1	Background	303	33	Reimbursement (EU and USA)	
30.2	PET Before Radiation Therapy	303	33.1	PET Reimbursement: Europe	331
30.3	PET During Radiation Therapy	303		M. DIETLEIN	
30.4	Deoxygenation and PET	304	33.2	PET Reimbursement: United States	335
30.5	PET Imaging After Completion of Radiation Therapy	304		R. E. COLEMAN AND RUTH D. TESAR	
30.6	Diagnosing Recurrent Disease with PET . . .	306			
30.7	Timing of PET After Radiation Therapy . . .	306			
30.8	Summary	308			
				Subject Index	339